In 2010, it acquired Cyto Pulse, which had developed a new electroporation technology,[3] and in 2011 it paid €28 million for Cellartis, a Swedish biotechnology company.

[2] With the advent of the CRISPR (clustered regularly interspaced short palindromic repeat) genome editing technique, the Cellectis meganuclease technology became uneconomic, and by 2013 the company was close to bankruptcy.

It restructured, closed laboratories and reduced staff, and shifted research emphasis toward CAR-T technologies for cancer immunotherapy.

[13] In early September 2017, the FDA suspended Cellectis’ Phase I trials of UCART123 in the wake of the death of a BPDCN patient from cytokine release syndrome (CRS).

[14] Cellectis also has a phase 1 trial for UCART22 in B-cell acute lymphoblastic leukemia (B-ALL) and received an IND approval from the FDA on their UCARTCS1 product candidate in multiple myeloma.